– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Makers of the new Alzheimer's drug, Leqembi, say their twice-monthly infusion could be available in injection form at pharmacies by early 2025 — if all goes well in ongoing trials and the regulatory ...

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), is ...

-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the KRYSTEXXA patient experience -- DUBLIN--(BUSINESS WIRE)-- Horizon ...